[Lucentis in treatment of the wet-form of age-related macular degeneration--two years experience].
In a study group of 114 patients (39 males, 75 females) with mean age of 72, 5 years (from 52 to 89 years) with mean follow-up of 8 month we retrospectively studied the effectivity and safety of intravitreal aplication of ranibizumab = Lucentis in the case of wet form of age-related macular degeneration (AMD). All patients met the inclusion criteria. The treatmet was realized on outpatient basis under strict application protocol. In the follow-up period the visual acuity improved in 66 patients (57%), stabilization was achieved in 17 patients (24.9%). In a group of 31 patients (27.2%) the central acuity deteriorated. There were no peroperative complications. In the postoperative period we observed in 22 patients temporary rise of intraocular pressure, in 21 patients suffusion, and in 3 patients there were subretinal haemorrhages found, in 1 case rupture of RPE and in 1 case anterior ischemic opticopathy was observed. Results observed in this study are in full compliance with PRONTO and PIER studies.